Definium Therapeutics, Inc. - DFTX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G | DRIEHAUS CAPITAL MANAGEMENT LLC | 6.64% | 6,537,202 | View |
| Feb 17, 2026 | SCHEDULE 13G | Avoro Capital Advisors LLC | 5.08% | 5,000,000 | View |
| Feb 17, 2026 | SCHEDULE 13G | Behzad Aghazadeh | 5.08% | 5,000,000 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Commodore Capital LP | 7.2% | 7,428,775 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Commodore Capital Master LP | 7.2% | 7,428,775 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Robert Egen Atkinson | 7.2% | 7,428,775 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Michael Kramarz | 7.2% | 7,428,775 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Deep Track Capital, LP | 5.54% | 5,676,540 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Deep Track Biotechnology Master Fund, Ltd. | 5.54% | 5,676,540 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | David Kroin | 5.54% | 5,676,540 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Deep Track Capital, LP | 6.87% | 5,500,000 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Deep Track Biotechnology Master Fund, Ltd. | 6.87% | 5,500,000 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | David Kroin | 6.87% | 5,500,000 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.